Posted by Gary Schwitzer in Drug industry
As he so often does, Merrill Goozner offers some important historical perspective to the news, as he headlined it: “Xigris Pulled – $1 Billion Later.” Excerpt:
“Another over-hyped and over-marketed drug bites the dust. Eli Lilly earlier this week pulled Xigris from the market after a clinical trial showed it provided no benefit for hospital patients with septic shock. From the start, critical clinicians questioned the efficacy of this drug, which is used to treat sepsis, a hospital-acquired systemic infection that often strikes the elderly in the wake of major operations. The Food and Drug Administration approved the drug in 2001 after a single, small trial showed a 28-day survival benefit. The FDA approval came despite half the members of an advisory panel voting against the drug.
Caution should have been the order of the day for physicians treating patients with this life-threatening condition. The company took an opposite path. It launched a “surviving sepsis” campaign that won endorsement from 11 professional societies (although the Infectious Disease Society of America did not join the campaign). Many of the docs who served on the guideline-writing panels for those professional societies earned consulting fees from Eli Lilly, according to a 2006 article in the New England Journal of Medicine questioning the ethics of the Lilly campaign. Sales of the biologic, which never reaching the blockbuster status hoped for by the company, soared to more than $200 million a year.”
Here’s my piece, “Eli Lilly not lily-white on Xigris promotion?” from almost exactly 5 years ago today.